PL1625166T3 - Przeciwciała przeciwko masp-2 - Google Patents

Przeciwciała przeciwko masp-2

Info

Publication number
PL1625166T3
PL1625166T3 PL04732276T PL04732276T PL1625166T3 PL 1625166 T3 PL1625166 T3 PL 1625166T3 PL 04732276 T PL04732276 T PL 04732276T PL 04732276 T PL04732276 T PL 04732276T PL 1625166 T3 PL1625166 T3 PL 1625166T3
Authority
PL
Poland
Prior art keywords
masp
antibodies
Prior art date
Application number
PL04732276T
Other languages
English (en)
Inventor
Flemming Larsen
Ulla Wahlers
Original Assignee
Helion Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helion Biotech Aps filed Critical Helion Biotech Aps
Publication of PL1625166T3 publication Critical patent/PL1625166T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL04732276T 2003-05-12 2004-05-12 Przeciwciała przeciwko masp-2 PL1625166T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300716 2003-05-12
EP04732276.3A EP1625166B1 (en) 2003-05-12 2004-05-12 Antibodies to masp-2
PCT/DK2004/000338 WO2004106384A1 (en) 2003-05-12 2004-05-12 Antibodies to masp-2

Publications (1)

Publication Number Publication Date
PL1625166T3 true PL1625166T3 (pl) 2015-08-31

Family

ID=33483731

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11172040T PL2374819T3 (pl) 2003-05-12 2004-05-12 Przeciwciała przeciwko MASP-2
PL04732276T PL1625166T3 (pl) 2003-05-12 2004-05-12 Przeciwciała przeciwko masp-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11172040T PL2374819T3 (pl) 2003-05-12 2004-05-12 Przeciwciała przeciwko MASP-2

Country Status (11)

Country Link
US (8) US9096676B2 (pl)
EP (2) EP2374819B1 (pl)
CN (1) CN1798769A (pl)
CY (2) CY1116506T1 (pl)
DK (2) DK2374819T3 (pl)
ES (2) ES2541134T3 (pl)
HU (2) HUE024996T2 (pl)
PL (2) PL2374819T3 (pl)
PT (2) PT2374819T (pl)
SI (2) SI2374819T1 (pl)
WO (1) WO2004106384A1 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
PL2374819T3 (pl) 2003-05-12 2017-09-29 Helion Biotech Aps Przeciwciała przeciwko MASP-2
CA2847677C (en) * 2004-06-10 2018-05-01 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201561B2 (en) * 2004-06-10 2016-03-31 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en) * 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2011265532B2 (en) * 2004-06-10 2014-04-24 Omeros Corporation Methods for treating conditions associated with MASP-2-dependent complement activation
WO2007079755A1 (en) 2006-01-12 2007-07-19 Janus Beierholm Holding Aps Reimmunization and antibody design
WO2007095154A2 (en) * 2006-02-10 2007-08-23 The Brigham And Women's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
PL2027158T3 (pl) 2006-05-02 2013-02-28 Carviar Aps Sposób immunizacji gatunków ptaków
CA2723219A1 (en) * 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
DK2488203T3 (en) * 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
KR20220044616A (ko) 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013201779B2 (en) * 2011-05-04 2016-01-07 Omeros Corporation Compositions for inhibiting MASP-2 dependent complement activation
CA2832871C (en) * 2011-05-04 2019-01-15 Omeros Corporation Compositions for inhibiting masp-2 dependent complement activation
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
CN103614341B (zh) * 2013-09-02 2016-07-13 杨旸 抗甘露糖结合凝聚素的单克隆抗体及试剂盒
SI3057993T1 (sl) * 2013-10-17 2021-03-31 Omeros Corporation Postopki za zdravljenje bolezenskih stanj, povezanih z aktivacijo komplementov, odvisnih od MASP-2
CN107004624B (zh) * 2014-11-25 2020-06-16 应用材料公司 具有基板载体和净化腔室环境控制的基板处理系统、设备和方法
JP6682653B2 (ja) 2016-01-05 2020-04-15 ユニバーシティー オブ レスター 線維症の阻害を必要とする対象において線維症を阻害するための方法
BR112018069732A2 (pt) 2016-03-31 2019-02-05 Omeros Corporation métodos para prevenir, tratar, reverter e/ou retardar angiogênese em um sujeito mamífero, para tratar um sujeito que sofre de uma doença ou condição angiogênica ocular e para inibir angiogênese do tumor
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
TWI881481B (zh) 2017-08-15 2025-04-21 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
KR20210024003A (ko) * 2018-06-22 2021-03-04 오메로스 코포레이션 다양한 혈전성 질환 및 장애의 치료를 위한 masp-2 억제 조성물 및 방법
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
PH12021552817A1 (en) 2019-05-07 2022-09-28 Bayer Ag Masp inhibitory compounds and uses thereof
TWI867422B (zh) 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
EP4011904A1 (en) 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
WO2022096394A1 (en) 2020-11-04 2022-05-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CN115215937B (zh) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
US20240141069A1 (en) * 2021-06-08 2024-05-02 Shanghai Jemincare Pharmaceutical Co., Ltd Anti-masp-2 antibody and use thereof
WO2023274340A1 (en) * 2021-06-30 2023-01-05 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-masp-2 antibodies
CN116615544A (zh) * 2021-12-10 2023-08-18 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
EP4493597A1 (en) * 2022-03-18 2025-01-22 Inmagene Pte. Ltd. Masp-2-targetting antibodies and uses thereof
US12216123B2 (en) 2023-04-25 2025-02-04 Nuvance Health Extracellular vesicle derived MASP-2 directed cancer treatment methods
WO2025153000A1 (zh) * 2024-01-17 2025-07-24 信立泰(成都)生物技术有限公司 一种抗masp2抗体或其抗原结合片段及用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US558767A (en) 1896-04-21 Oyster-dredger
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6008017A (en) 1997-01-02 1999-12-28 Smithkline Beecham Corporation Human cardiac/brain tolloid-like protein
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US5955309A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation Polynucleotide encoding G-protein coupled receptor (H7TBA62)
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
RU2292217C2 (ru) 1999-05-14 2007-01-27 Стеффен ТИЭЛЬ Рекомбинантный маннан-связывающий лектин человека
EP1200127B1 (en) 1999-07-21 2008-06-25 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
JP2003508030A (ja) 1999-08-11 2003-03-04 キュラジェン コーポレイション 新規ポリペプチドおよびそれをコードする核酸
EP1204419A1 (en) 1999-08-13 2002-05-15 The Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
WO2001040451A2 (en) 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
EP2026073B1 (en) 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
AU2001279586A1 (en) 2000-07-13 2002-01-30 Jens Christian Jensenius Masp-2, a complement-fixing enzyme, and uses for it
US20020094332A1 (en) 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
EP1416962A4 (en) 2001-07-26 2006-05-24 Alexion Pharma Inc METHOD FOR IMPROVING THE COGNITIVE FUNCTION
EP1467801A1 (en) 2002-01-22 2004-10-20 Alexion Pharmaceuticals, Inc. Method of prophylaxis against large myocardial infarctions
CA2474645C (en) 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CN100519643C (zh) 2002-07-19 2009-07-29 奥默罗斯公司 可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料
CA2496834C (en) 2002-09-06 2014-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
AU2003283217A1 (en) 2002-12-03 2004-06-23 Aarhus Amt Method for determing predisposition to manifestation of immune system related diseases
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CN1750844B (zh) 2003-02-21 2010-09-08 健泰科生物技术公司 凝集素途径特异性补体抑制剂在制备用于预防或抑制组织损伤的药物中的用途
PL2374819T3 (pl) 2003-05-12 2017-09-29 Helion Biotech Aps Przeciwciała przeciwko MASP-2
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
EP1670910A1 (en) 2003-09-05 2006-06-21 Natimmune A/S Masp-2 crystal structure and uses thereof
WO2005118635A2 (en) * 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
CA2847677C (en) 2004-06-10 2018-05-01 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
KR101625961B1 (ko) * 2006-09-08 2016-05-31 애브비 바하마스 리미티드 인터루킨-13 결합 단백질

Also Published As

Publication number Publication date
PT2374819T (pt) 2017-07-04
US9096676B2 (en) 2015-08-04
US20070009528A1 (en) 2007-01-11
PT1625166E (pt) 2015-08-20
EP2374819A1 (en) 2011-10-12
HUE034760T2 (en) 2018-02-28
WO2004106384A1 (en) 2004-12-09
US20230058435A1 (en) 2023-02-23
SI1625166T1 (sl) 2015-08-31
ES2541134T3 (es) 2015-07-16
US11008405B2 (en) 2021-05-18
EP1625166A1 (en) 2006-02-15
CY1116506T1 (el) 2017-03-15
US20210221913A1 (en) 2021-07-22
DK1625166T3 (en) 2015-07-13
CY1119106T1 (el) 2018-02-14
ES2629344T3 (es) 2017-08-08
US20190144564A1 (en) 2019-05-16
US11225526B2 (en) 2022-01-18
SI2374819T1 (sl) 2017-09-29
EP2374819B1 (en) 2017-03-22
EP1625166B1 (en) 2015-04-08
PL2374819T3 (pl) 2017-09-29
US20160096897A1 (en) 2016-04-07
US20200216566A1 (en) 2020-07-09
US20210261688A1 (en) 2021-08-26
DK2374819T3 (en) 2017-06-06
US20200199252A1 (en) 2020-06-25
HUE024996T2 (en) 2016-01-28
US11008404B2 (en) 2021-05-18
CN1798769A (zh) 2006-07-05
US10189909B2 (en) 2019-01-29

Similar Documents

Publication Publication Date Title
PL1625166T3 (pl) Przeciwciała przeciwko masp-2
EP1616881A4 (en) ANTI-MPL ANTIBODIES
GB0426043D0 (en) Antibodies
PT1599504E (pt) Anticorpo modificado
IL202681A0 (en) Interleukin-10 antibodies
EP1648512A4 (en) ANTI-CD19 ANTIBODIES
ZA200604074B (en) Anti-IGFR1 antibody therapeutic combinations
GB0305702D0 (en) Bispecific antibodies
IL181575A0 (en) Anti-ox40l antibodies
SG136945A1 (en) Antibodies to m-csf
IL228032A0 (en) Antibodies
IL173557A0 (en) Variable antibodies
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
GB0420466D0 (en) Anti-glucan antibodies
AU2003218456A8 (en) Antibodies that specifically bind to gmad
EP1598368A4 (en) ANTI-PCI neutralizing ANTIBODY
ZA200701952B (en) Anti-OX40L antibodies
GB0306618D0 (en) Antibody
IL172511A0 (en) Specific human antibodies
GB0317974D0 (en) Novel antibodies
GB0329711D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies
GB0319118D0 (en) Variable antibodies
GB0319345D0 (en) Variable antibodies
GB0217742D0 (en) Novel antibodies